{"filing":{"accession_number":"0001140361-26-035195","cik":"0001658247","ticker":"CRNX","company_name":"Crinetics Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"ef20081409_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/ef20081409_8k.htm"},"events":[{"id":30843,"run_id":28283,"accession_number":"0001140361-26-035195","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Crinetics Pharmaceuticals completed a merger transaction in which it became a wholly owned subsidiary of Parent for approximately $10.0 billion in aggregate consideration, resulting in a change of control. At the Effective Time, all Company Common Stock was converted into merger consideration, all directors resigned, all officers were removed, and the company's certificate of incorporation and bylaws were amended. Multiple agreements including equity plans and a sales agreement were terminated in connection with the merger consummation.","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33567,"accession_number":"0001140361-26-035195","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses termination of multiple agreements \"in connection with the consummation of the Merger\" and \"effective as of the Effective Time,\" indicating completion of a material merger transaction. Item 1.02 covers termination of material definitive agreements, but the context here is a merger consummation, which is the underlying material M\u0026A activity. The terminations of equity plans and the sales agreement are ancillary consequences of the merger closing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33568,"accession_number":"0001140361-26-035195","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.01 explicitly addresses \"Completion of Acquisition or Disposition of Assets,\" which is a core M\u0026A event. The filing references an Introductory Note containing the substantive details of the transaction completion. Acquisition or disposition completions are material events affecting the registrant's asset base and strategic position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33569,"accession_number":"0001140361-26-035195","item_number":"3.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"While Item 3.01 nominally covers delisting, the core event disclosed here is the consummation of a merger (\"Closing Date,\" \"Effective Time,\" \"Merger had been consummated\") that triggers the delisting and deregistration. The delisting is a consequence of the merger's completion, not the primary material event. The merger itself is the transformative transaction that would materially affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33570,"accession_number":"0001140361-26-035195","item_number":"3.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 3.03 discloses material modification to security holder rights resulting from a merger completion. The prose explicitly states that at the Effective Time, Company Common Stock was converted into merger consideration and stockholders ceased to have rights except to receive that consideration. This is the terminal event of a merger transaction, which is a material acquisition/change of control event. The cross-references to Items 2.01 (Completion of Acquisition or Disposition) and 5.01 (Changes in Control) confirm the merger has closed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33571,"accession_number":"0001140361-26-035195","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses the consummation of a merger resulting in a change of control, with Crinetics becoming a wholly owned subsidiary of Parent for approximately $10.0 billion in aggregate consideration. This is a material acquisition/change of control event, the core subject of ma_activity classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33572,"accession_number":"0001140361-26-035195","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"This Item 5.02 disclosure centers on the consummation of a merger (the \"Effective Time\") and the resulting wholesale replacement of the board and executive officers. While the Item nominally covers director and officer changes, the operative event is the completion of the Merger Agreement and the transition of control to the Surviving Corporation. The resignation of all eight directors and removal of all incumbent officers are consequences of the merger's consummation, not standalone governance events. This is a material acquisition/change of control event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":30844,"run_id":28283,"accession_number":"0001140361-26-035195","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"summary":"The company's certificate of incorporation and bylaws were amended pursuant to the merger agreement's effective time, reflecting routine post-closing corporate restructuring.","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33573,"accession_number":"0001140361-26-035195","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This Item 5.03 disclosure describes routine amendments to the company's certificate of incorporation and bylaws pursuant to a merger agreement's effective time. While the amendments are formally required disclosures, they are administrative in nature and do not themselves constitute a material event to investors—the material event is the underlying merger (which would be disclosed separately under Item 1.01 or 2.01). The disclosure is a standard governance filing documenting the post-closing restructuring of corporate documents.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33567,"accession_number":"0001140361-26-035195","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses termination of multiple agreements \"in connection with the consummation of the Merger\" and \"effective as of the Effective Time,\" indicating completion of a material merger transaction. Item 1.02 covers termination of material definitive agreements, but the context here is a merger consummation, which is the underlying material M\u0026A activity. The terminations of equity plans and the sales agreement are ancillary consequences of the merger closing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-09-01"},{"id":33568,"accession_number":"0001140361-26-035195","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 2.01 explicitly addresses \"Completion of Acquisition or Disposition of Assets,\" which is a core M\u0026A event. The filing references an Introductory Note containing the substantive details of the transaction completion. Acquisition or disposition completions are material events affecting the registrant's asset base and strategic position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-09-01"},{"id":33569,"accession_number":"0001140361-26-035195","item_number":"3.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"While Item 3.01 nominally covers delisting, the core event disclosed here is the consummation of a merger (\"Closing Date,\" \"Effective Time,\" \"Merger had been consummated\") that triggers the delisting and deregistration. The delisting is a consequence of the merger's completion, not the primary material event. The merger itself is the transformative transaction that would materially affect a reasonable investor's assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-09-01"},{"id":33570,"accession_number":"0001140361-26-035195","item_number":"3.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 3.03 discloses material modification to security holder rights resulting from a merger completion. The prose explicitly states that at the Effective Time, Company Common Stock was converted into merger consideration and stockholders ceased to have rights except to receive that consideration. This is the terminal event of a merger transaction, which is a material acquisition/change of control event. The cross-references to Items 2.01 (Completion of Acquisition or Disposition) and 5.01 (Changes in Control) confirm the merger has closed.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-09-01"},{"id":33571,"accession_number":"0001140361-26-035195","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 5.01 discloses the consummation of a merger resulting in a change of control, with Crinetics becoming a wholly owned subsidiary of Parent for approximately $10.0 billion in aggregate consideration. This is a material acquisition/change of control event, the core subject of ma_activity classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-09-01"},{"id":33572,"accession_number":"0001140361-26-035195","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"This Item 5.02 disclosure centers on the consummation of a merger (the \"Effective Time\") and the resulting wholesale replacement of the board and executive officers. While the Item nominally covers director and officer changes, the operative event is the completion of the Merger Agreement and the transition of control to the Surviving Corporation. The resignation of all eight directors and removal of all incumbent officers are consequences of the merger's consummation, not standalone governance events. This is a material acquisition/change of control event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-09-01"},{"id":33573,"accession_number":"0001140361-26-035195","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This Item 5.03 disclosure describes routine amendments to the company's certificate of incorporation and bylaws pursuant to a merger agreement's effective time. While the amendments are formally required disclosures, they are administrative in nature and do not themselves constitute a material event to investors—the material event is the underlying merger (which would be disclosed separately under Item 1.01 or 2.01). The disclosure is a standard governance filing documenting the post-closing restructuring of corporate documents.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T13:28:55.612327+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-09-01"}]}